High matrix metalloproteinase production correlates with immune activation and leukocyte migration in leprosy reactional lesions

Infection and Immunity

Volumn 78, Issue 3, 2010, Pages 1012-1021

  Teles, Rosane M B ^a   Teles, Rose B ^a   Amadeu, Thais P ^a,b   Moura, Danielle F ^a   Mendonça Lima, Leila ^a   Ferreira, Helen ^a   Santos, Ítalo M C F ^a   Nery, José A C ^a   Sarno, Euzenir N ^a   Sampaio, Elizabeth P ^a,c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORDANE; GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENSITOMETRY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; LEPROMATOUS LEPROSY; LEPROSY; LEUKOCYTE MIGRATION; MALE; MYCOBACTERIUM LEPRAE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; TUBERCULOID LEPROSY; ZYMOGRAPHY;

ADULT; CELL MOVEMENT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATION MEDIATORS; LEPROSY; LEUKOCYTES; MALE; MATRIX METALLOPROTEINASES; MICROSCOPY, CONFOCAL; MIDDLE AGED; MYCOBACTERIUM LEPRAE; SKIN; YOUNG ADULT;

EID: 77349103860     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00896-09     Document Type: Article

References (43)

1. Abraham, M., S. Shapiro, N. Lahat, and A. Miller. 2002. The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int. Immunol. 14:1449-1457.
2. Benbow, U., and C. E. Brinckerhoff. 1997. The AP-1 site and MMP gene regulation: what is all the fuss about? Matrix Biol. 15:519-526.
3. Bond, M., R. P. Fabunmi, A. H. Baker, and A. C. Newby. 1998. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett. 435:29-34.
4. Chizzolini, C., R. Rezzonico, C. De Luca, D. Burger, and J. M. Dayer. 2000. Th2 cell membrane factors in association with IL-4 enhance matrix metalloproteinase-1 (MMP-1) while decreasing MMP-9 production by granulocyte-macrophage colony-stimulating factor-differentiated human monocytes. J. Immunol. 164:5952-5960.
5. Das, S. K., S. Yano, J. Wang, D. R. Edwards, H. Nagase, and S. K. Dey. 1997. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev. Genet. 21:44-54.
6. Fayyazi, A., S. Schweyer, B. Eichmeyer, J. Herms, B. Hemmerlein, H. J. Radzun, and H. Berger. 2000. Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. Arch. Dermatol. Res. 292:384-390.
7. Gerlach, R. F., and J. E. Tanus-Santos. 2005. Circulating matrix metalloproteinase-9 levels as a biomarker of disease. Clin. Cancer Res. 11:8887.
8. Gomez, D. E., D. F. Alonso, H. Yoshiji, and U. P. Thorgeirsson. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74:111-122.
9. Gunduz, K., P. Demireli, I. Inanir, and N. Nese. 2006. Expression of matrix metalloproteinases (MMP-2, MMP-3, and MMP-9) and fibronectin in lichen planus. J. Cutan. Pathol. 33:545-550.
10. Han, Y. P., T. L. Tuan, H. Wu, M. Hughes, and W. L. Garner. 2001. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF-(kappa)B mediated induction of MT1-MMP. J. Cell Sci. 114:131-139.
11. Harris, J. E., M. Fernandez-Vilaseca, P. T. Elkington, D. E. Horncastle, M. B. Graeber, and J. S. Friedland. 2007. IFNgamma synergizes with IL-1beta to up-regulate MMP-9 secretion in a cellular model of central nervous system tuberculosis. FASEB J. 21:356-365.
12. Harris, J. E., J. A. Green, P. T. Elkington, and J. S. Friedland. 2007. Monocytes infected with Mycobacterium tuberculosis regulate MAP kinasedependent astrocyte MMP-9 secretion. J. Leukoc. Biol. 81:548-556.
13. Herman, M. P., G. K. Sukhova, W. Kisiel, D. Foster, M. R. Kehry, P. Libby, and U. Schönbeck. 2001. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest. 107:1117-1126.
14. Ho, H. H., T. T. Antoniv, J.-D. Ji, and L. B. Ivashkiv. 2008. Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-γ via superinduction of ATF-3 and suppression of AP-1. J. Immunol. 181:5089-5097.
15. Jung, K., M. Lein, C. Laube, and R. Lichtinghagen. 2001. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta 314:241-244.
16. Llano, E., A. M. Pendas, V. Knauper, T. Sorsa, T. Salo, E. Salido, G. Murphy, J. P. Simmer, J. D. Bartlett, and C. Lopez-Otin. 1997. Identification and structural and functional characterization of human enamelysin (MMP-20). Biochemistry 36:15101-15108.
17. Ma, Z., M. J. Chang, R. C. Shah, and E. N. Benveniste. 2005. Interferon-γ-activated STAT-1α suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. J. Leukoc. Biol. 78:515-523.
18. McCawley, L. J., and L. M. Matrisian. 2001. Tumor progression: defining the soil round the tumor seed. Curr. Biol. 11:R25-R27.
19. Modlin, R. L., J. Melancon-Kaplan, S. M. Young, C. Pirmez, H. Kino, J. Convit, T. H. Rea, and B. R. Bloom. 1988. Learning from lesions: patterns of tissue inflammation in leprosy. Proc. Natl. Acad. Sci. U. S. A. 85:1213-1217.
20. Moraes, M. O., N. C. Duppre, P. N. Suffys, A. R. Santos, A. S. Almeida, J. A. Nery, E. P. Sampaio, and E. N. Sarno. 2001. Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. Immunogenetics 53:45-47.
21. Moraes, M. O., E. N. Sarno, R. M. Teles, A. S. Almeida, B. C. Saraiva, J. A. Nery, and E. P. Sampaio. 2000. Anti-inflammatory drugs block cytokine mRNA accumulation in the skin and improve the clinical condition of reactional leprosy patients. J. Invest. Dermatol. 115:935-941.
22. Moura, D. F., R. M. Teles, M. M. Ribeiro-Carvalho, R. B. Teles, I. M. Santos, H. Ferreira, T. O. Fulco, J. A. Nery, E. P. Sampaio, and E. N. Sarno. 2007. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction. Br. J. Dermatol. 157:273-283.
23. Nakada, M., D. Kita, K. Futami, J. Yamashita, N. Fujimoto, H. Sato, and Y. Okada. 2001. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma. J. Neurosurg. 94:464-473.
24. Nguyen, J., J. Gogusev, P. Knapnougel, and B. Bauvois. 2006. Protein tyrosine kinase and p38 MAP kinase pathways are involved in stimulation of matrix metalloproteinase-9 by TNF-alpha in human monocytes. Immunol. Lett. 106:34-41.
25. Niimi, Y., R. Pawankar, and S. Kawana. 2006. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int. Arch. Allergy Immunol. 139:104-113.
26. Nikkola, J., P. Vihinen, M. S. Vuoristo, P. Kellokumpu-Lehtinen, V. M. Kahari, and S. Pyrhonen. 2005. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin. Cancer Res. 11:5158-5166.
27. Okamoto, T., T. Akuta, F. Tamura, A. van Der Vliet, and T. Akaike. 2004. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol. Chem. 385:997-1006.
28. Quiding-Jarbrink, M., D. A. Smith, and G. J. Bancroft. 2001. Production of matrix metalloproteinases in response to mycobacterial infection. Infect. Immun. 69:5661-5670.
29. Ratzinger, G., P. Stoitzner, S. Ebner, M. B. Lutz, G. T. Layton, C. Rainer, R. M. Senior, J. M. Shipley, P. Fritsch, G. Schuler, and N. Romani. 2002. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J. Immunol. 168:4361-4371.
30. Ridley, D. S., and W. H. Jopling. 1966. Classification of leprosy according to immunity. A five-group system. Int. J. Lepr. Other Mycobact. Dis. 34:255-273.
31. Robak, E., A. Wierzbowska, M. Chmiela, L. Kulczycka, A. Sysa-Jedrejowska, and T. Robak. 2006. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Mediators Inflamm. 2006:1-7.
32. Robinson, S. C., K. A. Scott, and F. R. Balkwill. 2002. Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNFalpha. Eur. J. Immunol. 32:404-412.
33. Sampaio, E. P., M. O. Moraes, J. A. Nery, A. R. Santos, H. C. Matos, and E. N. Sarno. 1998. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL). Clin. Exp. Immunol. 111: 300-308.
34. Sampaio, E. P., and E. N. Sarno. 1998. Expression and cytokine secretion in the states of immune reactivation in leprosy. Braz. J. Med. Biol. Res. 31:69-76.
35. Saren, P., H. G. Welgus, and P. T. Kovanen. 1996. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J. Immunol. 157:4159-4165.
36. Sawicki, G., Y. Marcoux, K. Sarkhosh, E. E. Tredget, and A. Ghahary. 2005. Interaction of keratinocytes and fibroblasts modulates the expression of matrix metalloproteinases-2 and -9 and their inhibitors. Mol. Cell. Biochem. 269:209-216.
37. Sheen, P., C. M. O'Kane, K. Chaudhary, M. Tovar, C. Santillan, J. Sosa, L. Caviedes, R. H. Gilman, G. Stamp, and J. S. Friedland. 2009. High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur. Respir. J. 33:134-141.
38. Shubayev, V. I., M. Angert, J. Dolkas, W. M. Campana, K. Palenscar, and R. R. Myers. 2006. TNFalpha-induced MMP-9 promotes macrophage recruitment into injured peripheral nerve. Mol. Cell. Neurosci. 31:407-415.
39. Sottrup-Jensen, L., O. Sand, L. Kristensen, and G. H. Fey. 1989. The alphamacroglobulin bait region. Sequence diversity and localization of cleavage sites for proteinases in five mammalian alpha-macroglobulins. J. Biol. Chem. 264:15781-15789.
40. Sottrup-Jensen, L. 1989. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J. Biol. Chem. 264:11539-11542.
41. Teles, R. M., S. L. Antunes, M. R. Jardim, A. L. Oliveira, J. A. Nery, A. M. Sales, E. P. Sampaio, V. Shubayev, and E. N. Sarno. 2007. Expression of metalloproteinases (MMP-2, MMP-9, and TACE) and TNF-alpha in the nerves of leprosy patients. J. Peripher. Nerv. Syst. 12:195-204.
42. Teles, R. M., M. O. Moraes, N. T. Geraldo, A. M. Salles, E. N. Sarno, and E. P. Sampaio. 2002. Differential TNFalpha mRNA regulation detected in the epidermis of leprosy patients. Arch. Dermatol. Res. 294:355-362.
43. Williams, L. M., D. L. Gibbons, A. Gearing, R. N. Maini, M. Feldmann, and F. M. Brennan. 1996. Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA synovial membrane cell cultures. J. Clin. Invest. 97:2833-2841.